AbbVie: Phase 3 Elagolix Study Shows Positive Top-Line Results

(RTTNews) - AbbVie (ABBV), in cooperation with Neurocrine Biosciences Inc. (NBIX), announced positive top-line results from the first of two ongoing Phase 3 clinical trials, designed to evaluate the efficacy and safety of elagolix in premenopausal women with endometriosis. Results from the trial show that after six months of treatment, both doses of elagolix (150 mg once daily and 200 mg twice daily) met the study's co-primary endpoints of reducing scores of non-menstrual pelvic pain and menstrual pain, associated with endometriosis, at month three, as well as month six.

A second Phase 3, randomized, multinational, double-blind, placebo-controlled trial (M12-671) evaluating elagolix in patients with moderate-to-severe endometriosis-related pain is ongoing and results are expected in late 2015.